Kornimate/medical-research-clean huggingface dataset:
pilot study on the effect of oral controlled-release alpha-lipoic acid on oxidative stress in adolescents with type 1 diabetes mellitus

Conditions: Diabetes Mellitus, Type 1

Summary: the long-term effects of high blood sugar include blindness, kidney failure, and nerve damage that can ultimately cause loss of limbs. research has shown that high blood sugar increases the amount of reactive oxygen species (ros) produced in diabetics, and that the increase in ros causes damage to eyes, kidneys, and nerves by a process called "oxidative stress." we postulate that alpha-lipoic acid, a potent anti-oxidant, can stop ros from forming, thereby preventing long-term complications in diabetes. in this pilot study, we will be giving 30 teenagers with type 1 diabetes (t1d) controlled-release alpha-lipoic acid for 3 months, and comparing the amount of oxidative stress before and after treatment. ten teenagers with t1d will receive placebo instead of alpha-lipoic acid and undergo the same research protocol to aid in validation of outcome measures.


Eligibility criteria:
inclusion criteria: 1. subjects must be pubertal (defined as tanner stage ii or greater), or post-pubertal, with an upper age limit of 21 years. 2. subjects must have diabetes by 1997 ada criteria: 1. fasting plasma glucose \>= 126 mg/dl, or 2. 2 hour postprandial glucose \>= 200 mg/dl 3. subjects must have history of least one auto-antibody associated with t1d, either glutamic acid decarboxylase (gada) or islet cell autoantigen 512 (ica512), or history of diabetic ketoacidosis. exclusion criteria: 1. subjects must not have history of eye, kidney or nerve damage 2. subjects must not be deemed unable or unlikely to comply with the protocol. children who are unable to swallow pills, or are unwilling to take pills twice daily will be excluded from the study. -

Keywords: diabetes mellitus, type 1 lipoic acid oxidative stress
neurobiological and neurocognitive disturbances in first-episode schizophrenia

Conditions: Schizophrenia

Summary: we want to relate disturbances in first-episode schizophrenic patients in serotonin 5-ht2a receptors, brain structure, brain function, and information processing to each other and to psychopathology. additionally, we want to examine the influence of 5-ht2a receptor blockade on these disturbances. we expect disturbances in the serotonergic system at baseline to correlate with specific structural and functional changes and with disruption in information processing as measured with psychophysiological and neurocognitive methods - and we expect 5-ht2a receptor blockade to reverse some of the functional and cognitive impairments. we do not expect any effect of treatment on brain structure

patients and matched healthy controls are examined at baseline and again after the patients have been treated for 6 months with a combined 5-ht2a- and dopamine d2- receptor blocker. we have chosen the atypical antipsychotic compound, quetiapine, for the present study since this drug is characterized by a fast koff/low affinity for the dopamine d2 receptors. the purpose of the study is to examine pathophysiological and neuropsychological mechanisms - not treatment effects. we want to characterize neurobiological and functional endophenotypes or vulnerability indicators and to study their stability over time and their relation to treatment and contemporary psychopathology. to the extent that candidate endophenotypes can be characterized as stable and independent of treatment and contemporary psychopathology they will be analysed together with similar findings from previous (identical)cohorts of schizophrenic patients. specific disturbances will also be related to candidate genes for schizophrenia.

Eligibility criteria:
inclusion criteria: * first-episode schizophrenia. the controls are matched for age, gender and parental socioeconomic status exclusion criteria: * previous antipsychotic treatment, mental retardation, organic brain damage, and for the controls a psychiatric diagnosis or first-degree relatives with a psychiatric diagnosis

Keywords: first-episode altanserin 5-ht2a receptors mri fmri ppi p300 p50 gating endophenotypes vulnerability indicators quetiapine
clonal hematopoiesis of indeterminate potential in venous thromboembolism

Conditions: Venous Thromboembolism

Summary: the aim of the study is to investigate the existence of clonal hematopoiesis of indeterminate potential (chip) in patients with a history of venous thromboembolism. the study investigators make the assumption that these patients present mutations involved in chip occurrence.


Eligibility criteria:
inclusion criteria: * men and women over 50 years old who have consulted at the hematology laboratory of the nîmes university hospital for the occurrence or history of venous thromboembolism * patient who has accepted that their dna was kept and used in the context of research on venous thromboembolism (biobank (registration number dc-2008-290 and authorization number ac-2008-107)) exclusion criteria: * patients less than 50 years old * patient who has refused that their dna was kept and used in the context of research on venous thromboembolism

Keywords: clonal hematopoiesis of indeterminate potential
oral cladribine b-cell study

Conditions: Multiple Sclerosis

Summary: to study the impact of cladribine on peripheral and intrathecal b-cell, plasma cells, t cells and tregs

primary: to quantify the temporal changes of memory b cells (cd19+/cd27+/igd-/+), plasmablasts (cd19-/cd138+/cd38+) and t cells (cd4/cd45ra-/+, ccr7-/+, cd8+/cd45ra-/+/ccr7-/+), tregs (cd4/cd8)/cd25+/cd127-/fox3 p+) in the peripheral venous blood of pwms with rrms over 96w of treatment with oral cladribine. these will be compared to the populations of non-memory or class-switched b cells (immature/transitional b cells cd10+/cd38+/cd19+, immature regulatory b cells cd10+/cd38+/cd19+/cd24+/il-10+, mature b cells cd10-/cd38+/cd19+). secondary: 1. to study the effects of oral cladribine on: 1. csf ocbs and free immunoglobulin kappa and lambda light chain levels (flc). 2. csf markers of inflammation, in particular cxcl-13 and urine markers of inflammation (neopterin). 3. csf markers of neuroaxonal damage, in particular free neurofilament light chains. 4. on the peripheral repertoire b-cells (immunoglobulin) and t-cells (t cell receptor) and plasma cells (soluble receptors). 2. to compare csf ocb positivity and csf light chain levels with a contemporary control group of alemtuzumab treated pwms (historical data). tertiary: 1. to compare b and t cell repertoire with a contemporary control group of alemtuzumab treated pwms (historical data). 2. to evaluate the effect of changes in the immune cell profile on clinical measures of disability, mri activity and proms.

Eligibility criteria:
inclusion criteria: * patients with ms who are being treated with oral cladribine at barts health nhs trust will be approached to participate in this study. * patients must be willing and able to undergo lumbar punctures * patients who are ocb positive in their csf (previous diagnostic lumbar puncture) exclusion criteria: * ineligible for oral cladribine under nhs england prescribing guidelines and those participating in magnify-ms study (cladribine tablets in active ms) * unsuitable to have a lumbar puncture, for example spinal deformity, tethered cord syndrome or the use of aspirin or anticoagulants, and those unable to comply with study requirements, including frequency of visits and lumbar punctures. * presence of comorbidities in which the administration of cladribine is contraindicated. * abnormal baseline investigations (wbc\ /3x upper limit of normal of site reference ranges, potassium \ 5.5mmol/l, sodium \ 130 umol/l)

Keywords: ms
interdisciplinary e-health based follow-up of preterm born children

Conditions: Preterm Birth

Summary: the aim of the study is to assess mental and somatic symptoms of preterm born children at the ages of 2, 5 and 10 by a multidisciplinary team and to evaluate an app that screens for these symptoms. furthermore, there will be an evaluation of an intervention by our multidisciplinary team that provides recommendations for further treatment and diagnostic procedures of the children.

* at first, there will be focus groups with experts and affected families to finalize and optimize the study procedure. after that, 90 children will be recruited (ages 2, 5 and 10) * t0: app-questions for the children at the ages of 5 and 10 and the parents of all children to mental, somatic and sleep problems of the children and well-being of the parents, sleep tracking and recording of a sleep sequence of the children; differentiated examinations and questionnaires to mental and somatic problems of the children by interdisciplinary study team * interdisciplinary study team meeting to generate recommendations for the families * interdisciplinary study team recommendations for the families * t1: comparable to t0 but only measurements that were assessed with questionnaires/at home plus post-experimental questionnaire * focus groups with participating families and the study team experts for evaluation of the study procedure and intervention

Eligibility criteria:
inclusion criteria: * female and male preterm born children (\<32 week of pregnancy) that are treated at the clinic in tübingen and their parents * existence of systematical neonatal data and consent of the care person to use this data * existence of the data of the 2 year regular follow-up (for the 5 and 10 year olds) exclusion criteria: * lack of access to a mobile phone/tablet including internet access * insufficient knowledge of the german language of both parents

Keywords: preterm born children ehealth development somatic and mental problems interdisciplinary care
promoting in-home activities at a memory & aging clinic

Conditions: MCI; Mild Dementia

Summary: the objective of the proposed study, "promoting in-home activities at a memory \& aging clinic (pro-home mec)", is to assess and improve the feasibility of a physical activity (pa) intervention and the measurement of cognitive outcomes in a memory clinic setting for inactive older adults with mild cognitive impairment (mci) or mild dementia and to examine how and improve the feasibility and acceptability of the procedures.


Eligibility criteria:
inclusion criteria: * age 50+ * fluent in english * diagnosed with mci or mild dementia * physically inactive (\< 150 min/wk of planned pa) * able to sit in a chair independently for 15+ minutes exclusion criteria: * have significant mental or physical disabilities that lead to inability to perform pa safely (e.g., major stroke) * severe uncompensated hearing or visual loss * having insufficient decisional capacity to consent to participate in research. * lack of safety awareness * unwilling to be assigned to pro-home mec or control group * currently participating in pa intervention research
ocular manifestation and related risk factors of covid-19 associated mucormycosis: a multicenter study in iran

Conditions: COVID-19; Mucormycosis

Summary: coronavirus disease 2019 (covid-19) infection caused by the novel severe acute respiratory syndrome coronavirus 2 (sars-cov-2) may manifest as a variety of disease patterns, ranging from mild to life-threatening pneumonia. mucormycosis has been suspected to cause significant morbidity in infected people since the outbreak of the covid-19 pandemic. individuals who require hospitalization and intensive care are more vulnerable, as they have reached an advanced stage of their disease. investigators will discuss the major risk factors, ocular presentation, and outcome of mucormycosis in individuals infected with sars-cov-2 in this study. from august 2021 to january 2022, a cross-sectional descriptive multicenter investigation would be conducted on patients with biopsy-confirmed mucormycosis and rtpcr confirmed covid19. demographic data, the time interval between covid19 and mucormycosis, underlying systemic disorders, clinical characteristics, disease course, and outcomes would be analyzed.

investigators will achieved the following data from the participants: 1. demographic 2. past medical/habitual history 3. covid-19 status and related risk factors 4. mucormycosis status and related risk factors 5. ocular examination and imaging 6. follow-up

Eligibility criteria:
inclusion criteria: * diagnosed case of mucormycosis in covid-19 pandemic exclusion criteria: * people with acute or severely ill conditions that prevent them from ophthalmic examination. * patient, or legal representative opposing the pursuit of the research

Keywords: coronavirus disease-associated mucormycosis covid-19 rhino-orbital-cerebral mucormycosis mucormycosis
the healthy lifestyle study

Conditions: Obesity

Summary: the purpose of this study is to determine if an internet-based intervention will be effective in improving the lifestyle and weight of an obese employee population. the intervention will last 12 months, and includes a weight tracker, a food intake tracker, an activity tracker, a calorie balance tool, an electronic discussion board, and electronic greeting cards.

the study will compare two groups over time, one of which will utilize the electronic tools, and one of which will not. the samples will be drawn from the employees of a metro-milwaukee hospital, and will consist of obese (body mass index, or bmi, of 30 or greater) employees only. the primary outcome will be change in weight over the study time period as measured by the bmi. secondary outcome measures will include quality of life, blood pressure, tests of blood sugar, cholesterol, presence of depression, lifestyle wellness score, health care costs and productivity.

Eligibility criteria:
inclusion criteria: * obesity as defined by a bmi of 30 or greater * the ability to speak and understand english * health insurance coverage through first health (aurora's employee insurance plan) * not currently on another formal weight management program * not currently taking any weight loss medications * not currently disabled in such a way that participation would be precluded
an ambispective cohort study of orelabrutinib in combination with standard treatment regimen for untreated dlbcl

Conditions: Lymphoma, Large B-Cell, Diffuse Neoplasms by Histologic Type

Summary: to retrospectively collect information on dlbcl patients treated with orelabrutinib in combination with standard first-line regimens, pooled analysis of the association between recent efficacy and patient characteristics (including biomarkers) in different types of patients to assess the predictive value of ctdna for prognosis and subsequent therapeutic adjustments during treatment; prospective observation to collect information on the efficacy of orelabrutinib in combination with standard treatment regimens in specific types of populations (with a focus on genotyped patients such as mcd, bn2 and n1 subtypes) to validate the predictive value of ctdna in diagnosis and treatment. standard treatment regimens include the r-chop regimen and the pola-r-chop regimen.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years diffuse large b-cell lymphoma (dlbcl) diagnosed by histopathology of the tumour, without any previous anti-tumour therapy or after ≤2 cycles of r-chop(like) or pola-r-chp therapy only * have a clear efficacy evaluation * patients eligible for non-gcb or extra-nodal or dual expression or who, in the judgement of the investigator, would benefit from treatment with orelabrutinib following genetic testing. * patients treated with at least 2 cycles of orelabrutinib in combination with an r-chop(like) or pola-r-chp regimen exclusion criteria: * lymphoma involving the central nervous system or soft meningeal metastases * transforming lymphoma, i.e. from other types of lymphoma such as follicular lymphoma, marginal zone lymphoma or chronic lymphocytic leukaemia or small b-cell lymphoma * primary mediastinal large b-cell lymphoma * patients with poorly controlled cardiovascular disease, infectious disease, etc.
impact of prophylactic antibiotics on bloodstream infections after liberation from extracorporeal membrane oxygenation

Conditions: Catheter-Related Infections

Summary: the goal of this prospective interventional study is to evaluate the impact of antibiotic prophylaxis on bloodstream infections after liberation of extracorporeal membrane oxygenation therapy. the main questions aims to answer are: • does application of vancomycine prior to ecmo liberation have an impact of bloodstream infections? participants will get 1 dose of vancomycine i.v. (15-20 mg per kgkg) prior to liberation of ecmo. researchers will compare this interventional group to a group without antibiotic prophylaxis.


Eligibility criteria:
inclusion criteria: * adult patients older than 18 years * ecmo-therapy exclusion criteria: * patients younger than 18 years * fever \>38,5°c * pregnancy * antibiotic treatment with vancomycine, linezolid, daptomycin or tygacil on the day of liberation * prior adverse events after application of vancomycine
effect of parental enteral nutrition on quality of parent-child interactions

Conditions: Premature; Parent-Child Relations

Summary: studies underline both the importance of the link and contact that occurs in the earliest days of life and the need to involve parents early with their premature child. however, the impact of parental nutrition on the later active nutrition and on the quality of parent-child interactions is currently unknown. premiam study investigates whether active parental participation in enteral nutrition improves the interactions between the infant and his parents, making them more sensitive to their baby's signals and promoting their relational adjustment.

the importance of parental participation in the feeding of preterm infants has been highlighted by gianni. in his study of 81 preterm infants in the tertiary centre , the early parental bottle feeding and the skin-to-skin contact were factors promoting withdrawal from enteral nutrition. moreover, actively participate in care even complex, is desired by parents. recently, a study compared 10 parent-child dyads and showed that enteral nutrition pushed by a parent (parental nutrition, np) in comparison of the electric syringe pump , allowed a better perception of the tube by the parents and gave them a sense of utility. the same team randomized 17 preterm infants, born after 28 wa( week amenorrhoea), to receive or not à parent-pushed enteral nutrition the child's behavior changes during nutrition were analyzed in both arms, after scoring of the videos feeding according to the nicap® ( individualized neonatal assessment and developmental care program) method. signs of well-being and relaxation of members were more present in case of parental involvement in the delivery of nutrition. these preliminary studies suggest that parental nutrition is well tolerated and improves the comfort of the child and parent during nutrition. however, the impact of parental nutrition on the subsequent active nutrition and on the quality of parent-child interactions is currently unknown.

Eligibility criteria:
inclusion criteria: children born before 30 sa age of child at start of study: 32 sa exclusion criteria: * child with ongoing infection, neurological pathology more than one desaturation and/or bradycardia per hour within 12 last hours balloon ventilation in last 12 hours * medical contraindication to oral nutrition * intubated child * parents with a disabling mental illness * parents not available * minor parents * parents under guardianship or protection of justice * refusal to sign consent * parents not affiliated with a social security system

Keywords: premature child at 32 of gestational age enteral nutrition skin to skin push on syringe pump parent-child relations
study to determine effectiveness of activation mist on facial skin wrinkles

Conditions: Skin Wrinkles on Face and Neck Areas

Summary: to determine the effect of activation mist (am) on skin wrinkles and appearance.

this study aims to study the effects of activation mist ( am) on skin wrinkles. it contains a proprietary blend of minerals and nutritional supplements which is patented as "liquidized infrared negative ion activation energy". active ingredients include sodium bicarbonate, potassium bicarbonate, sodium carbonate, strontium carbonate, gold nanoparticles, calcium, germanium, selenium , zinc, sugar and water. when applied to the skin , it has been shown to reduce the appearance of wrinkles by stimulation of skin fibroblasts to produce new collagen while removing aging dermis cells, facilitate the production of fibrillin proteins and protect the skin from ultraviolet rays.

Eligibility criteria:
inclusion criteria: 1.male and female subjects aged 30 to 80 years of age with significant facial wrinkles as assessed by the study physician. exclusion criteria: 1. women who are pregnant or lactating. 2. subjects with skin conditions that are deemed by the investigator to interfere with the results of this study , including but not limited to: uncontrolled acne, rosacea, atopic dermatitis. 3. subjects with clinically significant cardiovascular, neurological, renal, endocrine or hematological abnormalities uncontrolled on current therapy. 4. subjects with history of skin malignancy 5. subjects with signs of recent sunburn 6. use of any of the following medications, within 1 week specified of visit 1 1. systemic steroids 2. topical steroids used on the face 3. topical facial preparations including but not limited to: salicylic acid and other acne products, tacrolimus, pimecrolimus.

Keywords: wrinkles activation mist